Brought to you by 
UK diagnostics firm Quotient nets $37.2mm in US IPO
28 Apr 2014
Executive Summary
UK transfusion diagnostics company Quotient Ltd. netted $37.2mm in its US initial public offering of 5mm shares at $8, well below its initial anticipated $14-16 price range (the company later lowered its expectations to $9-11). Investors also received three-month warrants to buy 4mm shares at $8.80.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Hematology, Coagulation
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
UK diagnostics firm Quotient nets $37.2mm in US IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice